AC
ANIP icon

Alexandria Capital’s ANI Pharmaceuticals ANIP Stock Holding History

Alexandria Capital’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-7
Closed – – 250
2017
Q3 		$0 Hold
7
– – ﹤0.01% 552
2017
Q2 		$0 Hold
7
– – ﹤0.01% 613
2017
Q1 		$0 Hold
7
– – ﹤0.01% 605
2016
Q4 		$0 Hold
7
– – ﹤0.01% 586
2016
Q3 		$0 Hold
7
– – ﹤0.01% 599
2016
Q2 		$0 Hold
7
– – ﹤0.01% 597
2016
Q1 		$0 Hold
7
– – ﹤0.01% 599
2015
Q4 		$0 Hold
7
– – ﹤0.01% 642
2015
Q3 		$0 Hold
7
– – ﹤0.01% 587
2015
Q2 		$0 Hold
7
– – ﹤0.01% 602
2015
Q1 		$0 Hold
7
– – ﹤0.01% 616
2014
Q4 		$0 Hold
7
– – ﹤0.01% 572
2014
Q3 		$0 Hold
7
– – ﹤0.01% 560
2014
Q2 		$0 Hold
7
– – ﹤0.01% 581
2014
Q1 		$0 Hold
7
– – ﹤0.01% 580
2013
Q4 		$0 Hold
7
– – ﹤0.01% 594
2013
Q3 		$0 Buy
+7
New +$50 ﹤0.01% 611

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Alexandria Capital's ANIP Position: Q4 2017 in Review

Alexandria Capital sold out of ANI Pharmaceuticals (ANIP) in Q4 2017, closing a stake of 7 shares.

Alexandria Capital first reported a position in ANIP in Q3 2013 and held it in 17 quarters. The position peaked at $0 in Q3 2017. 163 funds tracked by Wall St. Rank hold ANIP as of Q4 2017.

  • Alexandria Capital reported no remaining ANI Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Alexandria Capital sold 7 ANI Pharmaceuticals shares in Q4 2017.
  • Alexandria Capital first reported a position in ANI Pharmaceuticals in Q3 2013 and held it in 17 quarters.
  • Alexandria Capital's ANI Pharmaceuticals position peaked at $0 in Q3 2017.
  • 163 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2017.

Based on Alexandria Capital's 13F filing for Q4 2017, filed 9 Feb 2018.